These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial. Gonzalez-Salinas R; Karpecki P; Yeu E; Holdbrook M; Baba SN; Ceballos JC; Massaro-Corredor M; Corredor-Ortega C; Ramos-Betancourt N; Quiroz-Mercado H Cont Lens Anterior Eye; 2022 Aug; 45(4):101492. PubMed ID: 34332895 [TBL] [Abstract][Full Text] [Related]
4. Collarette Elimination and Gonzalez-Salinas R; Yeu E; Holdbrook M; Baba SN; Ceballos JC; Massaro-Corredor M; Corredor-Ortega C; Ramos-Betancourt N; Quiroz-Mercado H J Ocul Pharmacol Ther; 2021 Oct; 37(8):479-484. PubMed ID: 34415795 [No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials. Muhammad Muneeb Akhtar S; Fareed A; Sohaib Asghar M; Mumtaz M; Kaur S Cont Lens Anterior Eye; 2024 Jun; 47(3):102148. PubMed ID: 38514290 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Yeu E; Holdbrook M; Baba SN; Ceballos JC; Massaro-Corredor M; Corredor-Ortega C; Ramos-Betancourt N; Quiroz-Mercado H; Gonzalez-Salinas R Ocul Immunol Inflamm; 2023 Oct; 31(8):1653-1661. PubMed ID: 35914297 [TBL] [Abstract][Full Text] [Related]
7. A Systematic Review and Meta-Analysis of the Safety and Efficacy of 0.25% Lotilaner Ophthalmic Solution in the Treatment of Demodex Blepharitis. Awan B; Elsaigh M; Tariq A; Badee M; Loomba A; Khedr Y; Abdelmaksoud A Cureus; 2024 Jan; 16(1):e52664. PubMed ID: 38380217 [TBL] [Abstract][Full Text] [Related]
8. Xdemvy Gupta AK; Mann A; Vincent K; Abramovits W Skinmed; 2024; 22(1):61-66. PubMed ID: 38494618 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Gonzalez-Salinas R; Yeu E; Holdbrook M; Baba SN; Ceballos JC; Massaro-Corredor M; Corredor-Ortega C; Ramos-Betancourt N; Quiroz-Mercado H J Ophthalmol; 2021; 2021():3862684. PubMed ID: 34603770 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study. Sadri E; Paauw JD; Ciolino JB; Nijm L; Simmons B; Meyer J; Gaddie IB; Berdy GJ; Holdbrook M; Baba SN; Jalalat P; Yeu E Cornea; 2024 Nov; 43(11):1368-1374. PubMed ID: 38334465 [TBL] [Abstract][Full Text] [Related]
11. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Davey PG; Farid M; Karpecki P; Gaddie IB; Chan A; Mun J; Neervannan S; Yeu E Healthcare (Basel); 2024 Jul; 12(15):. PubMed ID: 39120190 [No Abstract] [Full Text] [Related]
12. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Yeu E; Wirta DL; Karpecki P; Baba SN; Holdbrook M; Cornea; 2023 Apr; 42(4):435-443. PubMed ID: 35965392 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies. Talha M; Haris Ali M; Fatima E; Nadeem A; Ahmed A; Nashwan AJ Am J Ophthalmol; 2024 Aug; 264():8-16. PubMed ID: 38513948 [TBL] [Abstract][Full Text] [Related]
15. In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits. Sheppard JD; Cockrum PC; Justice A; Jasek MC Ophthalmol Ther; 2018 Jun; 7(1):157-165. PubMed ID: 29761367 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation. Venkatesh S; Richardson M J Ocul Pharmacol Ther; 2023 Nov; 39(9):622-630. PubMed ID: 37582270 [No Abstract] [Full Text] [Related]
17. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits. Weiss SL; Kramer WG J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703 [No Abstract] [Full Text] [Related]
18. Pharmacokinetics of Sirolimus Eye Drops Following Topical Ocular Administration in Rabbits. Lin J; Lu Z; Wang Y; Zhang J; Guo J; Huang Y; Lin B; Yang W J Ocul Pharmacol Ther; 2023 Dec; 39(10):735-743. PubMed ID: 37579189 [No Abstract] [Full Text] [Related]
19. Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits. Kallab M; Schuetzenberger K; Hommer N; Schäfer BJ; Schmidl D; Bergmeister H; Zeitlinger M; Tan A; Jansook P; Loftsson T; Stefansson E; Garhöfer G Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34070168 [TBL] [Abstract][Full Text] [Related]